Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003722 | 0.81 | CYP1A2 (0.31) | TSHRCYP1A2FBP1 | |
| SCHEMBL14401558 | 0.80 | — | — | |
| SCHEMBL20034497 | 0.75 | CYP1A2 (0.34) | CYP1A2CES1 | |
| SCHEMBL10952709 | 0.74 | ALDH1A1 (0.34) | TSHRALDH1A1POLB | |
| SCHEMBL1101930 | 0.74 | — | — | |
| SCHEMBL1996650 | 0.74 | — | — | |
| SCHEMBL17085866 | 0.69 | — | — | |
| SCHEMBL1271486 | 0.66 | CA1 (0.37) | TSHRCYP1A2FBP1CA1CA2 | |
| SCHEMBL14891491 | 0.57 | — | — | |
| SCHEMBL2003065 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055842-A1 | Combination Therapy with Glutaminase Inhibitors | CALITHERA BIOSCIENCES, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | LIANG YU (US) | 2018-03-01 | — | — | US | disclosed |
| US-20160287585-A1 | Treatment of Lung Cancer with Inhibitors of Glutaminase | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| US-9029531-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | TSHR 4546/4885CYP1A2 807/4885FBP1 50/4885 |
| US-20180055842-A1 | Combination Therapy with Glutaminase Inhibitors | GLS, GLS2, GLUL | TSHR 3464/4885CYP1A2 2399/4885FBP1 46/4885 |
| US-20160287585-A1 | Treatment of Lung Cancer with Inhibitors of Glutaminase | KRAS, GLS, GLUL | TSHR 3286/4885CYP1A2 3565/4885FBP1 285/4885 |
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | TSHR 2853/4885CYP1A2 1354/4885FBP1 88/4885 |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | TSHR 3853/4885CYP1A2 1481/4885FBP1 45/4885 |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | TSHR 4360/4885CYP1A2 3097/4885FBP1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.